Guo-Zhen Wu Selected Research

Sirolimus (Rapamycin)

5/2018

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guo-Zhen Wu Research Topics

Disease

2	Rheumatoid Arthritis 07/2018 - 01/2017
2	Neoplasms (Cancer) 05/2018 - 06/2017
1	Inflammation (Inflammations) 12/2018
1	Dermatitis 07/2018
1	Multiple Myeloma 05/2018
1	Arthritis (Polyarthritis) 01/2017

Drug/Important Bio-Agent (IBA)

2	Interleukin-1 (Interleukin 1)IBA 07/2018 - 01/2017
1	delavatine AIBA 12/2018
1	isoquinolineIBA 12/2018
1	AlkaloidsIBA 12/2018
1	CytokinesIBA 12/2018
1	EmollientsIBA 07/2018
1	alantolactoneIBA 07/2018
1	isoalantolactoneIBA 07/2018
1	Dinitrochlorobenzene (DNCB)IBA 07/2018
1	Interleukin-4 (Interleukin 4)IBA 07/2018
1	Sirolimus (Rapamycin)FDA Link 05/2018
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 05/2018
1	Mechanistic Target of Rapamycin Complex 2IBA 05/2018
1	ResveratrolIBA 05/2018
1	TOR Serine-Threonine KinasesIBA 05/2018
1	SesquiterpenesIBA 06/2017
1	CollagenIBA 01/2017
1	Interleukin-6 (Interleukin 6)IBA 01/2017

Therapy/Procedure

2	Therapeutics 05/2018 - 01/2017
1	Oral Administration 01/2017